Drug intelligence / Profile preview

ST004

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

ST004 is a liposomal formulation of an organogold complex developed as an antimelanoma agent. It has demonstrated in vitro antiproliferative activity against melanoma cell lines and exerts cell cycle alterations. In vivo studies in murine models of melanoma have also shown its therapeutic potential. The drug's mechanism of action involves the inhibition of Aquaglyceroporin-3 (AQP3) activity.

Targets

AQP3 (Aquaporin-3 channel protein)

Beyond the preview

Go deeper on ST004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST004.

Explore the full profile